Life MD Financial Results
Clear strategy focused on scaling high-value revenue
streams
Virtual Primary Care
RexMD
Partnerships
Key Priorities
Continue to scale weight management/GLP-1 offering
Launch cardiovascular health and hormone therapy offerings
Launch commercial health insurance programs in 10 states
Prepare Medicare/Medicaid infrastructure for 2024 deployment
Goals
High Value Revenue Streams
With Long-Term Brand Equity
Differentiated Telehealth
Offerings With Strong
Retention
Double digit new patient growth in E.D. business
Build and cross-sell patients to men's health primary care
offerings
30%+ YoY Revenue Growth
With ~25% Adj. EBITDA
Margins
Execute strategic partnerships in GLP-1 space
Continue to build long-term partnerships with Life Sciences and
health-related companies
LifeMD Synonymous With
Highest Quality, Affordable
Virtual Care
(tirzepatide) injection
mounjaro™
10 0.5 mL
(semaglutide) injection
wegovy
NDC 0169-4524-0
2.4 mg/0.75 mL477211
OZEMPIC
For Single Patient Use Only
(semaglutide) injection
List: 452401
2.4 mg
For subcutaneou
-0-ma
12
Life MD+View entire presentation